Humana (HUM)
NYSE: HUM · Managed Health Care · Louisville, KY
Our rating: Cautious
Cautious reaffirmed at $423.22, high conviction, November 9, 2026.
Breaks if: The Cautious view is wrong if Humana reports a net margin above 2.5% — consistent with a genuine normalization in its medical cost ratio — in two consecutive quarterly filings within the next 12 months, accompanied by free cash flow recovering above $1.5B on a trailing-twelve-month basis. A sustained move above $550 within the next twelve months while margins remain at current levels would also suggest the market is pricing a recovery path the reported figures do not yet support.
Key figures
| Market value | $46.8B |
|---|---|
| Revenue, last 12 months | $154.2B |
| Net income, last 12 months | $1.2B |
| Free cash flow, last 12 months | $3.1B |
| Price to earnings | 37.6× |
| Free cash flow yield | 6.7% |
| Dividend yield | 0.9% |
| Operating margin | 1.5% |
| Return on equity | 6.7% |
| Beta to the S&P 500 | 0.39 |
| Volatility, annualized | 45.6% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $41.2B | 26.1% | $1.33 | $2.0B |
| June 30, 2026 | $40.9B | 26.2% | $5.73 | $1.8B |
| March 31, 2026 | $39.6B | 23.5% | $9.83 | $1.1B |
| December 31, 2025 | $32.5B | 11.3% | $-6.59 | −$1.9B |
| September 30, 2025 | $32.6B | 11.1% | $1.62 | $836M |
| June 30, 2025 | $32.4B | 9.6% | $4.51 | $1.2B |
| March 31, 2025 | $32.1B | 8.4% | $10.30 | $236M |
| December 31, 2024 | $29.2B | 10.4% | $-5.74 | −$682M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $39.6B: Claude 78%, Gemini 88%, Mistral 96%
- Diluted earnings per share are above zero: Claude 8%, Gemini 8%, Mistral 30%
- Free cash flow for the quarter is above zero: Claude 18%, Gemini 25%, Mistral 20%
13 ledger entries and 58 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.